FUNDING
Company Profile
Drug Farm is a biotech developing AI-designed small-molecule drugs for rare and immune-inflammatory diseases, led by DF-003, a Phase 3 ALPK1 inhibitor for ROSAH syndrome.
Founded 2015Shanghai, China / New York, NY$138M raised
Investors
Shanghai Pudong Leading Area Investment CenterShanghai Puxing Collaborative Private Equity FundDetong CapitalWuXi AppTecBioVeda China FundYD CapitalBetta CapitalWedo Venture Management
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Jul 13, 2026 | Drug Farm Raises $55M Series D for Rare Disease Drug | $55M Series D | — | Story → |
Drug Farm FAQ
- How much has Drug Farm raised?
- Drug Farm has raised approximately $138M in total funding to date.
- Is Drug Farm publicly traded?
- No. Drug Farm is privately held.
- Who are Drug Farm's investors?
- Drug Farm's investors include Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund, Detong Capital, WuXi AppTec, BioVeda China Fund, YD Capital, Betta Capital, Wedo Venture Management.
Coverage Timeline
newest firstAll Coverage
FUNDING86% AI, top 5 = 73.1%
What Post-H1 Funding Data Already Shows for Q3
Helsing, Gauntlet and Drug Farm's rounds this week are early evidence that H1 2026's concentration pattern -- record capital, AI capturing 86%, the top five managers taking 73.1% -- is continuing into Q3, not reversing.
FUNDING
Drug Farm Raises $55M Series D for Rare Disease Drug
FUNDING$55M Series D
Drug Farm Raises $55M Series D for Rare Disease Drug
Biotech Drug Farm raised a $55 million Series D to advance DF-003, a Phase 3 ALPK1 inhibitor for rare autoinflammatory disorder ROSAH syndrome, alongside DF-006, a Phase 2 immunomodulator for hepatitis B and liver cancer.